Revvity account plan
Health science solutions revolutionizing healthcare
At a glance
Revvity is a Waltham-based health science company selling life sciences research tools, software and diagnostics, with FY2025 revenue of $2,856.1 million.
Revvity provides instruments, reagents, software and services for life sciences research, drug discovery and diagnostics, to pharmaceutical and biotech companies, laboratories, academic institutions, public health authorities and healthcare organizations in more than 160 countries. It is headquartered in Waltham, Massachusetts, listed on the NYSE as RVTY and part of the S&P 500. FY2025 revenue was $2,856.1 million (up 4%) and net income $241.2 million, with approximately 11,000 employees, roughly 80% of them outside the United States. Prahlad Singh is President and CEO.
Business units
Life Sciences Solutions
about 42% of FY2025 revenue ($1,194.7 million)Reagents (radiochemicals, assay technologies, Dharmacon and BioLegend antibodies) and instruments such as high-content screening systems, plate readers, in vivo imaging and liquid handling, sold to pharma, biotech, CROs and academia. Q3 2026 revenue rose to $312.1 million, with a growing high-content screening backlog linked to AI-driven demand.
Software (Signals)
about 8% of FY2025 revenue ($236.4 million)The Signals portfolio (Signals Notebook, ChemDraw, Clinical, Image Artist and DLX) plus ACD/Labs, acquired in 2026. Q3 2026 revenue grew to $67.5 million, and 2026 brought launches such as Signals LabGistics, Signals AI and an Anthropic Connector.
Immunodiagnostics
about 30% of FY2025 revenue ($869.9 million)EUROIMMUN autoimmune, allergy and infectious-disease testing, chemiluminescence analyzers, T-SPOT.TB tuberculosis testing and nucleic-acid isolation. Q3 2026 revenue fell to $202.2 million; the China Immunodiagnostics business, approximately 6% of FY2025 revenue, is being sold.
Reproductive Health
about 19% of FY2025 revenue ($555.0 million)Newborn and prenatal screening kits and instruments, the Revvity Omics clinical genomics lab network and ViaCord cord blood banking. Q3 2026 revenue rose to $147.1 million, and newborn screening is expanding into countries without screening programs.
Strategic priorities
- Serving AI-driven lab demand
- Revvity sees AI companies and pharma needing more wet-lab data; high-content screening orders outran near-term production capacity, and it is building additional capacity for 2027.
- Signals software launches
- 2026 is described as the most significant year of new product launches in Signals' history, including LabGistics, Synthetica, Signals AI and an Anthropic Connector, with ARR growth of 20% plus.
- Portfolio focus
- Revvity agreed on July 31, 2026 to sell its China Immunodiagnostics business and is adding ACD/Labs and Human Cell Design to Life Sciences.
- Footprint and cost efficiency
- Severance actions affected approximately 7% of the workforce in 2026 year to date, and R&D and manufacturing were consolidated at the Hopkinton, Massachusetts campus, with efficiency work in Lübeck and Hamburg.
- Diagnostics menu expansion
- Revvity launched the GSP T1D 3-Plex kit in Europe, its first step into early childhood screening, and is developing a broader T1D assay with Sanofi.
- AI and operational excellence
- The 10-K strategy includes advancing the use of AI in offerings and internal efficiency, operational excellence and disciplined capital allocation.
Latest results
In Q3 fiscal 2026 (quarter ended October 4, 2026) revenue rose 4% to $728.9 million, with Life Sciences up 11% to $379.6 million and Diagnostics down 2% to $349.3 million. Gross margin rose 380 bps to 57.4% and net income reached $62.3 million ($0.56 per diluted share). On a pro forma basis excluding China Immunodiagnostics, organic growth was 7% and adjusted operating margin 29.4%. For FY2026 management guides to pro forma organic growth of about 5%, an adjusted operating margin of 28.8% and adjusted EPS of $5.40-$5.45.
Investments and deals
- ACD/Labs acquisition
- Acquired in Q1 2026 for $72.0 million at closing plus up to $8.0 million contingent through 2028; a Toronto scientific software firm with about 200 employees.
- Human Cell Design acquisition
- Agreement signed in Q3 2026 for €45.0 million plus up to €8.0 million contingent, for a Toulouse biotech making human cell models for metabolic disease research.
- China Immunodiagnostics divestiture
- A definitive agreement was signed July 31, 2026, with closing expected by the end of FY2027 subject to Chinese approvals.
- Capex for digital and production
- Capex was $73.5 million in FY2025, and Revvity projects higher FY2026 capex for digital capabilities, product innovations and realigning its production infrastructure.
- Share buybacks and debt repayment
- It repurchased $820.8 million of shares in FY2025 and repaid the €500.0 million 1.875% notes in Q3 2026; $792.7 million remains under the $1.0 billion program.
Challenges and risks
- Research funding uncertainty
- U.S. funding and regulatory changes have created a more cautious spending environment for customers.
- China diagnostics pressure
- China testing policy changes hurt Diagnostics mix, China revenue fell to $425.1 million in FY2025, and APAC declined in Q3 2026.
- Tariffs and FX
- Tariffs added about $25 million to FY2025 cost of revenue, and approximately 60% of the business is conducted outside the U.S. in foreign currencies.
- Single-source suppliers and capacity
- Many critical raw materials have only one qualified source, and high-content screening orders outran near-term production capacity.
- Goodwill risk
- Life Sciences Solutions carries $4.5 billion of goodwill, with only a limited fair-value cushion at the November 2025 test.
What leadership says
“As customers look to build larger biological datasets to train and refine their AI models, they are going to need exponentially more data from the wet lab.”
“I believe our third quarter performance fully demonstrated, for the first time since the start of our recent transformation, what our true potential is as a company.”
“AI may accelerate hypothesis generation, but those hypotheses still need to be tested, validated and advanced through real-world biological data generation”
“are continuing to move back to more normalized spending behavior”
Where a supplier can help
- Manufacturing capacity for screening instruments
- High-content screening orders outran production capacity and capacity is being added for 2027, an opening for manufacturing equipment, automation and contract manufacturing suppliers.
- Supply chain resilience
- Single-source raw materials and tariff exposure favour suppliers that can qualify as second sources or cut landed cost.
- Software and AI partnerships
- The Signals launch wave and work with LLM providers create needs for cloud, AI and data integration partners.
- Integration of acquisitions and footprint moves
- Integrating ACD/Labs and Human Cell Design, the China divestiture and site consolidation at Hopkinton call for integration, IT separation and facilities support.
- Cost efficiency programmes
- Restructuring costs of $74.5 million over nine months of 2026 and continued efficiency work point to procurement, automation and shared-services offers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Revvity?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Revvity, Inc. Annual Report on Form 10-K for fiscal year 2025 (ended December 28, 2025)
- Revvity (NYSE: RVTY, S&P 500), headquartered in Waltham, Massachusetts, is a health science solutions company with two segments, Life Sciences and Diagnostics; approximately 11,000 employees at December 28, 2025, roughly 80% outside the U.S., selling in more than 160 countries.
- FY2025 revenue was $2,856.1 million, up 4% (about 1% from favorable FX): Life Sciences $1,431.1 million (+2%) and Diagnostics $1,424.9 million (+5%). Net income was $241.2 million ($2.07 per diluted share).
- Gross margin fell about 104 basis points to 54.8%, mainly on tariffs, FX and mix; tariffs added about $25 million to cost of revenue (net gross-margin impact about $20 million), mostly on products made in Europe and sold in the U.S.
- Segment operating margin: Life Sciences 32.0% (down 139 bps), Diagnostics 24.2% (down 194 bps, partly from China diagnostic testing policy changes).
- Software (Signals) grew $35.6 million to $236.4 million; Immunodiagnostics rose $41.3 million to $869.9 million and Reproductive Health $27.2 million to $555.0 million, while Life Sciences Solutions slipped $3.1 million to $1,194.7 million.
- Restructuring and other costs rose to $55.9 million; severance actions tied to facility consolidations and cost reduction affected approximately 5% of the workforce.
- Capital return: $820.8 million of share repurchases in FY2025, a new $1.0 billion buyback program (October 2025), $0.28 annual dividend; operating cash flow $589.0 million, capex $73.5 million, with capex projected to increase in FY2026 for digital capabilities, product innovation and production realignment.
- After year-end Revvity bought ACD/Labs (Toronto, about 200 employees, scientific software) for $72 million plus up to $8 million contingent; the strategy stresses R&D, acquisitions, AI in products and operations, and operational excellence.
- Key risks: government and research funding cuts making customers more cautious, tariffs and trade policy, China, FX (about 60% of business outside the U.S.), and a Life Sciences Solutions goodwill balance of $4.5 billion whose fair value exceeded carrying value by only 10-20%.
- Revvity, Inc. Quarterly Report on Form 10-Q for Q3 fiscal 2026 (quarter ended October 4, 2026)
- Q3 FY2026 (three months ended October 4, 2026) revenue was $728.9 million, up 4% from $698.9 million: Life Sciences $379.6 million (+11%) and Diagnostics $349.3 million (-2%).
- Life Sciences growth came from both Life Sciences Solutions (+$21.6 million, to $312.1 million) and Software (+$15.2 million, to $67.5 million). Diagnostics fell on Immunodiagnostics (-$10.5 million), partly offset by Reproductive Health (+$3.7 million).
- Gross margin rose 380 bps to 57.4% on favorable mix and restructuring benefit; operating margin rose 130 bps to 13.1%. Net income was $62.3 million ($0.56 per diluted share) versus $46.7 million.
- Nine-month revenue was $2,169.7 million (+4%), helped by an extra fiscal week; Life Sciences $1,100.1 million (+5%), Diagnostics $1,069.6 million (+3%).
- Restructuring and other costs were $74.5 million year to date; severance actions affected approximately 7% of the workforce over nine months (approximately 2% in Q3).
- Portfolio moves: ACD/Labs bought in Q1 for $72.0 million; agreement to buy Human Cell Design (Toulouse, human cell models for metabolic disease) for €45.0 million plus up to €8.0 million; definitive agreement (July 31, 2026) to divest the China Immunodiagnostics business, about 6% of FY2025 revenue, closing by end of FY2027.
- Tariff refunds: after the February 20, 2026 Supreme Court ruling on IEEPA tariffs, Revvity applied for $20.2 million of refunds.
- Balance sheet: the €500.0 million ($571.2 million) notes were repaid at maturity in Q3; cash $592.8 million; nine-month operating cash flow $484.5 million; $792.7 million left on the buyback, with no repurchases in Q3.
- Revvity Q3 2026 earnings conference call transcript
- CEO Prahlad Singh: Q3 2026 pro forma organic growth was 7%, above the mid-single-digit expectation. Pro forma adjusted operating margin was 29.4% and pro forma adjusted EPS $1.37, $0.08 above the guidance midpoint (pro forma excludes the China immunodiagnostics business being divested).
- Life Sciences grew 9% organically: reagents up high single digits (the strongest in several years), instruments up strong mid single digits, and Signals software up in the upper teens with 20%-plus ARR growth. Diagnostics grew 5%.
- AI-related demand is spreading beyond high-content screening. The high-content screening backlog keeps rising and capacity is being added; Singh: customers "are going to need exponentially more data from the wet lab".
- Signals launches in 2026 include LabGistics (AI-native workflow coordination), Synthetica Biodesign, Signals AI and an Anthropic Connector; 2026 is the biggest launch year in Signals' history.
- Diagnostics: launched in Europe the CE IVDR-certified GSP T1D 3-Plex kit for early type 1 diabetes detection, with a broader T1D assay in development with Sanofi. Diagnostics adjusted operating margin was 29.9% (over 30% excluding China immunodiagnostics).
- Guidance raised: FY2026 pro forma organic growth about 5% (started the year at 2-3%), adjusted operating margin 28.8%, adjusted EPS $5.40-$5.45 (about 12% growth). Q4 revenue midpoint about $755 million.
- CFO Max Krakowiak: free cash flow of $152 million in Q3 (99% conversion); net leverage 2.3x; 40%-plus incremental margins seen as sustainable; Genomics England is about $25 million of full-year revenue, with an extension under negotiation.
- Revvity Q2 2026 earnings call transcript
- Q2 2026 call (August 4, 2026): pro forma organic growth was 3% and pro forma adjusted EPS $1.41, well above guidance. About half of the EPS upside came from $16 million of tariff refunds and about a third from tax timing.
- Revvity signed a definitive agreement to divest its China immunodiagnostics business, called "a deliberate strategic decision"; closing is expected by end of 2027. Guidance is now pro forma, excluding it.
- Diagnostics grew 11% organically: reproductive health up mid-teens (newborn screening plus Genomics England), immunodiagnostics outside China up high single digits.
- Life Sciences fell 3% organically as Signals software declined about 20% against tough comparisons (APV still up double digits, ARR in the mid-20s); Life Sciences Solutions grew low single digits.
- AI demand: high-content screening orders (the new Opera Phenix OptIQ) outpaced production capacity. The instrument backlog was the strongest "in the past 3 to 4 years", including orders from non-traditional AI customers.
- Signals: BioDesign available, Synthetica in beta, Signals AI launched, an Anthropic MCP connector for Claude, and Signals for Startups; LabGistics was due later in 2026.
- Guidance raised: FY2026 organic growth 4-5% (from 3-4%), pro forma revenue $2.83-2.86 billion, adjusted operating margin 28.7%, adjusted EPS $5.30-5.40. About half the tariff windfall is being reinvested in strategic initiatives, supply chain and people.
- Cash and debt: Q2 free cash flow was $184 million (117% conversion); net leverage 2.5x; the €500 million note was retired in July.
Questions about Revvity
What does Revvity do?
Revvity sells instruments, reagents, software and services for life sciences research and drug discovery, and diagnostics such as immunodiagnostics and newborn screening.
What is Revvity's revenue?
FY2025 revenue was $2,856.1 million, up 4%; Q3 2026 revenue was $728.9 million.
How many employees does Revvity have?
Approximately 11,000 at December 28, 2025, roughly 80% of them outside the United States.
Who leads Revvity?
Prahlad Singh is President and CEO and Maxwell Krakowiak is SVP and CFO.
What is Revvity's strategy?
Grow in high-growth markets through innovation, Signals software and AI-driven lab demand, sharpen the portfolio by selling China Immunodiagnostics, and improve efficiency.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)